Inclusion body myositis

Curr Opin Rheumatol. 2002 Nov;14(6):653-7. doi: 10.1097/00002281-200211000-00004.


Inclusion body myositis (IBM) is an inflammatory myopathy with distinctive clinicopathologic features. The etiology of IBM remains elusive. The immune-mediated basis for this disease has been challenged by evidence implicating a number of divergent etiologic factors. These factors include mitochondrial deletions, nitric oxide induced oxidative stress, myonuclear breakdown, and abnormal accumulation within muscle fibers of brain-specific Alzheimer type proteins. The treatment of IBM with conventional immunosuppressive agents has been disappointing. Therapeutic approaches currently under study or consideration are beta-interferon and synthetic anabolic hormones.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Immune System / physiopathology
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Myositis, Inclusion Body* / drug therapy
  • Myositis, Inclusion Body* / etiology
  • Myositis, Inclusion Body* / pathology
  • Sex Factors
  • Treatment Outcome


  • Immunosuppressive Agents